Credit: Shutterstock photoAcceleron Pharma, a clinical stage biotech developing protein therapeutics for cancer and rare diseases, raised $84 million by offering 5.6 million shares at $15, at the high end of the $13 to $15 range. The Cambridge, MA-based company had originally planned to offer 4.7 million shares. Collaboration partner Celgene invested $10 million (0.7 million shares) in a concurrent private placement. Acceleron Pharma, which now commands a market cap of approximately $410 million, will list on the NASDAQ under the symbol XLRN. Citi and Leerink Swann acted as joint bookrunners on the deal.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
